Alopecia - Pipeline Review, H2 2019

Alopecia - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia - Pipeline Review, H2 2019, provides an overview of the Alopecia (Dermatology) pipeline landscape.

Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alopecia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 17, 7, 1, 15 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alopecia (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Alopecia - Overview
Alopecia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Alopecia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alopecia - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Allergan Plc
Almirall SA
Berg LLC
BiologicsMD Inc
BirchBioMed Inc
Brickell Biotech Inc
Cassiopea SpA
Concert Pharmaceuticals Inc
Dong-A Socio Holdings Co Ltd
Eli Lilly and Co
Energenesis Biomedical Co Ltd
Follica Inc
Histogen Inc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
JW Pharmaceutical Corp
Kuhnil Pharmaceutical Co Ltd
Lee's Pharmaceutical Holdings Ltd
Nepsone ehf
OliX Pharmaceuticals Inc
Pfizer Inc
Phio Pharmaceuticals Corp
Portola Pharmaceuticals Inc
Quark Pharmaceuticals Inc
Samumed LLC
Suzhou Ribo Life Sciences Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Tigo GmbH
Alopecia - Drug Profiles
(cyclosporine A + minoxidil + RT-175) - Drug Profile
AB-101 - Drug Profile
AB-102 - Drug Profile
AB-103 - Drug Profile
AB-105 - Drug Profile
AD-106 - Drug Profile
AD-208 - Drug Profile
AI-001 - Drug Profile
ATI-1777 - Drug Profile
ATI-501 - Drug Profile
ATI-502 - Drug Profile
baricitinib - Drug Profile
BBI-5000 - Drug Profile
BMD-1141 - Drug Profile
BNZ-1 - Drug Profile
BQ-A - Drug Profile
brepocitinib tosylate - Drug Profile
BRM-421 - Drug Profile
calcitriol - Drug Profile
CB-0311 - Drug Profile
cerdulatinib - Drug Profile
clascoterone - Drug Profile
CTP-543 - Drug Profile
CWL-080061 - Drug Profile
delgocitinib - Drug Profile
Drug for Alopecia Areata - Drug Profile
Drugs to Agonize Aryl Hydrocarbon Receptor for Alopecia, Vitiligo and Pemphigus - Drug Profile
ENERGIF-701 - Drug Profile
finasteride - Drug Profile
finasteride - Drug Profile
FOL-005 - Drug Profile
Gene Therapy to Inhibit SRD5A2 for Androgenic Alopecia - Drug Profile
HC-0100 - Drug Profile
HC-017AA - Drug Profile
HST-001 - Drug Profile
interferon beta-1b - Drug Profile
jaktinib hydrochloride - Drug Profile
KI-1104 - Drug Profile
KI-1105 - Drug Profile
KX-826 - Drug Profile
lithium gluconate - Drug Profile
Max-3 - Drug Profile
minoxidil - Drug Profile
minoxidil - Drug Profile
OLX-104 - Drug Profile
PF-06651600 - Drug Profile
Alopecia - Dormant Projects
Alopecia - Discontinued Products
Alopecia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Alopecia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Alopecia - Pipeline by Aclaris Therapeutics Inc, H2 2019
Alopecia - Pipeline by Allergan Plc, H2 2019
Alopecia - Pipeline by Almirall SA, H2 2019
Alopecia - Pipeline by Berg LLC, H2 2019
Alopecia - Pipeline by BiologicsMD Inc, H2 2019
Alopecia - Pipeline by BirchBioMed Inc, H2 2019
Alopecia - Pipeline by Brickell Biotech Inc, H2 2019
Alopecia - Pipeline by Cassiopea SpA, H2 2019
Alopecia - Pipeline by Concert Pharmaceuticals Inc, H2 2019
Alopecia - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2019
Alopecia - Pipeline by Eli Lilly and Co, H2 2019
Alopecia - Pipeline by Energenesis Biomedical Co Ltd, H2 2019
Alopecia - Pipeline by Follica Inc, H2 2019
Alopecia - Pipeline by Histogen Inc, H2 2019
Alopecia - Pipeline by Japan Tobacco Inc, H2 2019
Alopecia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Alopecia - Pipeline by JW Pharmaceutical Corp, H2 2019
Alopecia - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2019
Alopecia - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2019
Alopecia - Pipeline by Nepsone ehf, H2 2019
Alopecia - Pipeline by OliX Pharmaceuticals Inc, H2 2019
Alopecia - Pipeline by Pfizer Inc, H2 2019
Alopecia - Pipeline by Phio Pharmaceuticals Corp, H2 2019
Alopecia - Pipeline by Portola Pharmaceuticals Inc, H2 2019
Alopecia - Pipeline by Quark Pharmaceuticals Inc, H2 2019
Alopecia - Pipeline by Samumed LLC, H2 2019
Alopecia - Pipeline by Suzhou Ribo Life Sciences Co Ltd, H2 2019
Alopecia - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, H2 2019
Alopecia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2019
Alopecia - Pipeline by Tigo GmbH, H2 2019
Alopecia - Dormant Projects, H2 2019
Alopecia - Dormant Projects, H2 2019 (Contd..1), H2 2019
Alopecia - Dormant Projects, H2 2019 (Contd..2), H2 2019
Alopecia - Discontinued Products, H2 2019
List of Figures
Number of Products under Development for Alopecia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook